Clinical Trial

A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and With HIV.

Study acronym: IAVI C114
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1 Randomized Double Blinded Placebo Controlled, Dose Ranging Trial, of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine (GRAdHIVNE1 Vaccine), Administered to Healthy Adults Living without HIV and Living with HIV, in Southern Africa
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-26; most recent amendment 2026-02-11.
Status change: Not Yet Recruiting → Recruiting 2025-11-19
Trial Details
NCT Number NCT06617091
Lead Sponsor International AIDS Vaccine Initiative
Collaborators: Ragon Institute, ReiThera Srl, Mutala Trust
Conditions HIV
Enrollment 120 participants
Start Date 2025-07-28
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-13